CD274 and neoplasm: The figure also situates this strategy within the tumor microenvironment (TME)—highlighting dominant barriers (hypoxia, low pH, dense ECM, and immunosuppressive cells) and the potential for PD-L1 upregulation—and maps the translational pathway from preclinical studies to early clinical development.